Context
Founded in 2018, CanPharma is a German medicinal cannabis distributor that integrates pharma-industry best practices to deliver optimal cannabinoid-based treatments to patients
The Company is also one of the few German cannabis-focused companies to hold a GMP manufacturing licence enabling it to repackage, brand and release products into the EU
CanPharma also owns Spain-based Kalapa Clinic, the first medical consultancy in Europe focusing on medical cannabis, currently available online in six languages. In addition to patient consultancy, Kalapa also provides educational training to healthcare professionals
Health House International is a rapidly growing Australian Stock Exchange-listed group specialising in the distribution of medicinal cannabis products across Australasia, the United Kingdom and Europe
The all-stock acquisition of CanPharma provides Health House International with immediate access to Germany, the largest medical cannabis market in Europe, and opens the opportunity for expansion into other European markets - such as Spain - as legislation allows
CanPharma brings a very talented team including successful serial entrepreneurs, pharmacists, physicians and pharmaceutical distribution specialists; one of CanPharma´s management has joined the board of Health House and another has been appointed Group CEO
About CanPharma
Founded in 2018, CanPharma is German medicinal cannabis sales and distribution company that is integrating pharma-industry best practice to build brand and educate doctors and patients.
In Germany, CanPharma imports and distributes third party medicinal cannabis products as well as a number of CanPharma-branded products. CanPharma operates under a full pharmaceutical license according to the German Medicines Act, and is both GDP- & GMP-certified.
In addition, the company owns Kalapa Clinic with headquarters in Barcelona, the first medicinal cannabis consultancy in Europe which provides specialist advice to health care professionals and patients around the appropriate use of cannabis-based medicines in treating a range of conditions.
About Health House International (ASX:HHI)
Australian-listed Health House International (ASX:HHI) is an international pharmaceutical distributor specialising in the distribution of medicinal cannabis products.
The company currently distributes over 11+ products to pharmacies, prescribers, specialist clinics and researchers across Australasia.
The company also supplies pharmacies, hospitals, government departments, veterinarians and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe.
Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of CanPharma GmbH on the sale of the company to Health House International Ltd (ASX:HHI)
Bryan, Garnier & Co acted as Sole Advisor to CanPharma’s shareholders
Bryan, Garnier & Co supported the shareholders in preparing documentation, finding the best possible future partner, coordinating the deal process, organising due diligence and negotiating deal terms
Dr Henrik Sprengel, Founder and CEO of CanPharma noted: “Bryan, Garnier & Co’s expertise in healthcare, the team’s deep understanding of the medical cannabis space and its extensive reach has helped us assess the best strategic options for the company and led to a very positive and favorable transaction outcome. We appreciate the professionalism and long-term support of the team at Bryan, Garnier & Co, and look forward to working again with the firm in the future”
The sale of CanPharma to Health House International represents another successful transaction for the healthcare practice at Bryan, Garnier & Co. It demonstrates Bryan, Garnier & Co’s continued support for fast-growing medical cannabis players. Related transactions include the respective convertible bond issues of Aphria, Aurora and Canopy Growth, where Bryan Garnier & Co. acted as Co-Manager.
Share